Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 22Terminated 8Withdrawn 4Active not recruiting 3Unknown 2Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × romidepsin × Clear all
NCT02232516 2024-04-10

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Unknown
30 enrolled 17 charts
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT00431990 2011-08-12

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
40 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡